S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
Concord Medical (TASE:BLWV) Services Holdings Limited (NYSE:CCM), a healthcare provider specializing in cancer care, imaging diagnosis, and research and development in China, has disclosed through a Form 6-K filing with the U.S. Securities and Exchange Commission that its subsidiary, Shanghai Medstar, has increased its shareholding in Concord Healthcare Group Co., Ltd. The transaction occurred on Monday, involving the purchase of 95,400 H shares on the open market, which equates to approximately 0.01% of Concord Healthcare’s total issued shares as of the announcement date.
This latest acquisition follows a similar purchase by Shanghai Medstar on May 7, 2025. Concord Healthcare, a part of Concord Medical Services Holdings and listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code 2453.HK, has seen its shares traded actively since its listing on January 9, 2024.
Investors and interested parties can access transaction details related to Concord Healthcare on the Hong Kong Stock Exchange’s website. The 6-K form serves as a report of foreign private issuers to the SEC and provides monthly updates on significant corporate events.
The filing was signed by Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical Services Holdings Limited, on behalf of the registrant, as required by the Securities Exchange Act of 1934. The document confirms the company’s commitment to transparency and regulatory compliance in its financial reporting.
This information, based on the company’s latest SEC filing, indicates an ongoing interest by the controlling shareholder to increase its stake in Concord Healthcare. As the market processes this news, shareholders and analysts will be watching the company’s stock performance on the NYSE and HKSE closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.